Ulf Müller-Ladner, MD

JLU Campus KK
Bad Nauheim, Germany

-

Disclosure information not submitted.

Presentation(s):

• 1433: A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time